Display options
Cite
Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011;11:9doi: 10.1186/1472-6823-11-9.
Taylor, K., Gurney, K., Han, J., Pencek, R., Walsh, B., & Trautmann, M. (2011). Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC endocrine disorders, 119. https://doi.org/10.1186/1472-6823-11-9
Taylor, Kristin, et al. "Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years." BMC endocrine disorders vol. 11 (2011): 9. doi: https://doi.org/10.1186/1472-6823-11-9
Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011 Apr 29;11:9. doi: 10.1186/1472-6823-11-9. PMID: 21529363; PMCID: PMC3112417.
Copy Download .nbib Format: NLM
Share it on

BMC Endocr Disord. 2011 Apr 29;11:9. doi: 10.1186/1472-6823-11-9.

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

BMC endocrine disorders

Kristin Taylor, Kate Gurney, Jenny Han, Richard Pencek, Brandon Walsh, Michael Trautmann

Affiliations

  1. Amylin Pharmaceuticals, Inc,, 9360 Towne Centre Drive, San Diego, CA 92121, USA. [email protected].

PMID: 21529363 PMCID: PMC3112417 DOI: 10.1186/1472-6823-11-9

Abstract

BACKGROUND: The once-weekly (QW) formulation of the glucagon-like peptide-1 receptor agonist exenatide has been demonstrated to improve A1C, fasting plasma glucose (FPG), body weight, serum lipid profiles, and blood pressure in patients with type 2 diabetes through 52 weeks of treatment. In this report, we describe the 2-year results of the open-label, open-ended extension to the DURATION-1 trial of exenatide QW for type 2 diabetes.

METHODS: A 2-stage protocol was used: patients received either exenatide QW (2 mg) or exenatide twice daily for 30 weeks (5 μg for the first 4 weeks and 10 μg thereafter), followed by 1.5 years of treatment with exenatide QW (2 mg), for a total of 2 years (104 weeks) of exenatide treatment. Of the 295 (intent-to-treat [ITT]) patients who entered the trial, 73% (n = 216) completed 2 years of treatment (completer population). Baseline characteristics (mean ± SE) for these patients were: A1C, 8.2 ± 0.1%; FPG, 168.4 ± 43.0 mg/dL; body weight, 101.1 ± 18.7 kg; and diabetes duration, 7 ± 5 years.

RESULTS: In the completer population, significant improvements (LS mean ± SE [95% CI]) were maintained after 2 years of treatment in A1C (-1.71 ± 0.08% [-1.86 to -1.55%]), FPG (-40.1 ± 2.9 mg/dL [-45.7 to -34.5 mg/dL]), and body weight (-2.61 ± 0.52 kg [-3.64 to -1.58 kg]) compared with baseline. The percentages of patients who achieved an A1C of <7.0% and ≤6.5% at 2 years were 60% and 39%, respectively. A significant reduction in systolic blood pressure (SBP; -3.0 ± 1.0 mmHg [-4.9 to -1.1 mmHg]) was maintained through 2 years of treatment. Serum lipid profiles were also significantly improved, including triglycerides (geometric LS mean change from baseline, -15 ± 2.7% [-21% to -10%]), total cholesterol (-8.6 ± 2.8 mg/dL [-14.0 to -3.1 mg/dL]), and low-density lipoproteins (-4.5 ± 2.2 mg/dL [-8.9 to -0.01 mg/dL]). Changes in A1C, body weight, FPG, SBP, and lipids in the ITT population were similar to those seen in the completer population. Nausea (predominantly mild in intensity) was the most common adverse event, although the frequency and intensity of nausea decreased over time. No severe hypoglycemia was observed.

CONCLUSIONS: Exenatide QW was well tolerated during the 2-year treatment period. This study demonstrated sustained glucose control and weight loss throughout 2 years of treatment with exenatide QW.

TRIAL REGISTRATION: ClinicalTrials.gov NCT00308139.

References

  1. Diabetes Care. 2004 Nov;27(11):2628-35 - PubMed
  2. Diabetes Care. 2009 Jan;32(1):193-203 - PubMed
  3. JAMA. 1999 Jun 2;281(21):2005-12 - PubMed
  4. Ann Intern Med. 2007 Apr 3;146(7):477-85 - PubMed
  5. Ann Intern Med. 2009 Dec 15;151(12):854-60 - PubMed
  6. Diabetes Care. 2000 Jan;23 Suppl 1:S57-60 - PubMed
  7. Diabetes Care. 2007 Jun;30(6):1487-93 - PubMed
  8. Ann Intern Med. 2005 Oct 18;143(8):559-69 - PubMed
  9. Endocr Pract. 2009 Sep-Oct;15(6):540-59 - PubMed
  10. Diabetes Care. 2005 May;28(5):1083-91 - PubMed
  11. Diabetes Care. 2004 Jan;27 Suppl 1:S15-35 - PubMed
  12. Diabetes Care. 2010 Jun;33(6):1255-61 - PubMed
  13. Lancet. 1998 Sep 12;352(9131):837-53 - PubMed
  14. Curr Med Res Opin. 2008 Jan;24(1):275-86 - PubMed
  15. Diabet Med. 1998 Apr;15(4):297-303 - PubMed
  16. Curr Med Res Opin. 2008 Oct;24(10):2943-52 - PubMed
  17. Lancet. 2002 Mar 9;359(9309):824-30 - PubMed
  18. Regul Pept. 2004 Feb 15;117(2):77-88 - PubMed
  19. Diabetes Care. 2003 Mar;26(3):881-5 - PubMed
  20. Diabetes Care. 2006 Dec;29(12):2632-7 - PubMed
  21. Diabetes Care. 2005 May;28(5):1092-100 - PubMed
  22. BMJ. 1995 Jan 14;310(6972):83-8 - PubMed
  23. Diabetes Care. 2006 Sep;29(9):2140-57 - PubMed
  24. Diabetes. 2005 Jan;54(1):1-7 - PubMed
  25. Diabetologia. 2002 Feb;45(2):195-202 - PubMed
  26. Lancet. 2008 Oct 4;372(9645):1240-50 - PubMed
  27. Lancet. 2009 Jul 4;374(9683):39-47 - PubMed
  28. Diabet Med. 2009 Jul;26(7):722-8 - PubMed
  29. JAMA. 1997 Mar 19;277(11):925-6 - PubMed
  30. Clin Ther. 2007 Jan;29(1):139-53 - PubMed
  31. Diabetologia. 2003 Jan;46(1):3-19 - PubMed
  32. Diabetes Res Clin Pract. 2009 Jan;83(1):69-76 - PubMed
  33. Biomaterials. 1999 Jun;20(11):1057-62 - PubMed
  34. Lancet. 2010 Aug 7;376(9739):431-9 - PubMed
  35. J Biol Chem. 1993 Sep 15;268(26):19650-5 - PubMed
  36. Am J Med. 2009 Jun;122(6 Suppl):S37-50 - PubMed

Publication Types